Details for New Drug Application (NDA): 209309
✉ Email this page to a colleague
The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
Summary for 209309
Tradename: | NADOLOL |
Applicant: | Chartwell Rx |
Ingredient: | nadolol |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 209309
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
Approval Date: | Oct 5, 2017 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
Approval Date: | Oct 5, 2017 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 80MG | ||||
Approval Date: | Oct 5, 2017 | TE: | AB | RLD: | No |
Complete Access Available with Subscription